A detailed history of Lsv Asset Management transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 29,900 shares of PCRX stock, worth $617,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,900
Previous 16,133 85.33%
Holding current value
$617,136
Previous $462,000 2.6%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$11.7 - $28.46 $161,073 - $391,808
13,767 Added 85.33%
29,900 $450,000
Q2 2024

Aug 06, 2024

BUY
$25.5 - $31.51 $411,391 - $508,350
16,133 New
16,133 $462,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $946M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.